Vancouver, British Columbia–(Newsfile Corp. – June 22, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon” or the “Company”), a biotechnology company focused on developing psychedelic medicines to treat addiction, has announced an agreement with 3W Wellness Inc. ( “Third Wave”) to help drive brand awareness of the company’s Psychedelics Genetic Test kit…


Previous articleRed Light Holland to Partner with Leading Fresh and Dried Mushroom Producers on East Coast Facility
Next articleCybin Announces Completion of its 51st Pre-Clinical Psychedelic Molecule Study